by dyadic | Mar 20, 2025 | Press Releases
JUPITER, Fla., March 20, 2025 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale...
by dyadic | Mar 12, 2025 | Press Releases
JUPITER, Fla., March 12, 2025 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale...
by dyadic | Mar 6, 2025 | Press Releases
JUPITER, Fla., March 06, 2025 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale...
by dyadic | Jan 6, 2025 | Press Releases
JUPITER, Fla., Jan. 06, 2025 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale...
by dyadic | Nov 21, 2024 | Press Releases
Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable TherapeuticsJUPITER, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced today that it has been...
by dyadic | Nov 12, 2024 | Press Releases
Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology Platforms Alternative Proteins Demonstrated substantial revenue increase for Q3 2024, driven primarily by Dapibus™ license...
